Standard BioTools Inc [LAB] stock is trading at $1.38, up 0.73%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LAB shares have gain 7.81% over the last week, with a monthly amount glided 12.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Standard BioTools Inc [NASDAQ: LAB] stock has seen the most recent analyst activity on August 13, 2025, when TD Cowen downgraded its rating to a Hold but kept the price target unchanged to $1.55 for it. Previously, KeyBanc Capital Markets downgraded its rating to Sector Weight on February 27, 2025. On April 16, 2024, TD Cowen initiated with a Buy rating and assigned a price target of $3.50 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $3.25 on April 04, 2024. KeyBanc Capital Markets initiated its recommendation with a Overweight and recommended $4 as its price target on July 12, 2023.
Standard BioTools Inc [LAB] stock has fluctuated between $0.92 and $2.32 over the past year. Currently, Wall Street analysts expect the stock to reach $3.25 within the next 12 months. Standard BioTools Inc [NASDAQ: LAB] shares were valued at $1.38 at the most recent close of the market. An investor can expect a potential return of 135.51% based on the average LAB price forecast.
Analyzing the LAB fundamentals
Standard BioTools Inc [NASDAQ:LAB] reported sales of 154.24M for the trailing twelve months, which represents a drop of -41.51%. Gross Profit Margin for this corporation currently stands at 0.43% with Operating Profit Margin at -0.76%, Pretax Profit Margin comes in at -0.66%, and Net Profit Margin reading is -0.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.26 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Standard BioTools Inc’s Current Ratio is 5.16. Also, the Quick Ratio is 4.92, while the Cash Ratio stands at 1.62. Considering the valuation of this stock, the price to sales ratio is 3.42, the price to book ratio is 1.24.
Transactions by insiders
Recent insider trading involved Casdin Partners Master Fund, L, Director, that happened on Sep 09 ’25 when 100000.0 shares were purchased. Director, Casdin Partners Master Fund, L completed a deal on Sep 04 ’25 to buy 0.25 million shares. Meanwhile, Director Casdin Partners Master Fund, L bought 0.25 million shares on Sep 03 ’25.
